TECAN LIMITED
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Fabricated Structural Metal, Miscellaneous Structural Metal Work, Fabricated Metal Products, Not Elsewhere Classified, Manufacturing Industries, Not Elsewhere Classified), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about TECAN LIMITED
Live alerts from global media, monitored by Business Radar
2024-11-12 (nature.com)
Laboratory validation of a clinical metagenomic next-generation sequencing assay for respiratory virus detection and discovery
Tools for rapid identification of novel and/or emerging viruses are urgently needed for clinical diagnosis of unexplained infections and pandemic preparedness. Here we developed and clinically validated a largely automated metagenomic next-generation sequencing( mNGS) assay for agnostic detection of
Read more
2023-06-05 (nature.com)
Analyzing immune responses to varied mRNA and protein vaccine sequences - npj Vaccines
In response to the COVID-19 pandemic, different types of vaccines, such as inactive, live-attenuated, messenger RNA (mRNA), and protein subunit, have been developed against SARS-CoV-2. This has unintentionally created a unique scenario where heterologous prime-boost vaccination against a single
Read more
2022-08-11 (nature.com)
Rapid detection of SARS-CoV-2 RNA in saliva via Cas13 | Biomedical Engineering
Rapid nucleic acid testing is central to infectious disease surveillance. Here, we report an assay for rapid COVID-19 testing and its implementation in a prototype microfluidic device. The assay, which we named DISCoVER (for diagnostics with coronavirus enzymatic reporting), involves extraction-free sample lysis via shelf-stable and low-cost reagents, multiplexed isothermal RNA amplification followed by T7 transcription, and Cas13-mediated cleavage of a quenched fluorophore. The device consists of a single-use gravity-driven microfluidic cartridge inserted into a compact instrument for automated running of the assay and readout of fluorescence within 60 min. DISCoVER can detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in saliva with a sensitivity of 40 copies μl–1, and was 94% sensitive and 100% specific when validated (against quantitative PCR) using total RNA extracted from 63 nasal-swab samples (33 SARS-CoV-2-positive, with cycle-threshold values of 13–35).
Read more
2022-02-15 (nature.com)
Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) continue to wreak havoc across the globe. Higher transmissibility and immunologic resistance of VOCs bring unprecedented challenges to epidemic extinguishment. Here we describe a monoclonal antibody, 2G1, that neutralizes all current VOCs and has surprising tolerance to mutations adjacent to or within its interaction epitope. Cryo-electron microscopy structure showed that 2G1 bound to the tip of receptor binding domain (RBD) of spike protein with small contact interface but strong hydrophobic effect, which resulted in nanomolar to sub-nanomolar affinities to spike proteins. The epitope of 2G1 on RBD partially overlaps with angiotensin converting enzyme 2 (ACE2) interface, which enables 2G1 to block interaction between RBD and ACE2. The narrow binding epitope but high affinity bestow outstanding therapeutic efficacy upon 2G1 that neutralized VOCs with sub-nanomolar half maximal inhibitory concentration in vitro.
Read more
2021-03-25 (nature.com)
Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection | Biotechnology
Current serology tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies mainly take the form of enzyme-linked immunosorbent assays, chemiluminescent microparticle immunoassays or lateral flow assays, which are either laborious, expensive or lacking sufficient sensitivity and scalability. Here we present the development and validation of a rapid, low-cost, solution-based assay to detect antibodies in serum, plasma, whole blood and to a lesser extent saliva, using rationally designed split luciferase antibody biosensors. This new assay, which generates quantitative results in 30 min, substantially reduces the complexity and improves the scalability of coronavirus disease 2019 (COVID-19) antibody tests. This assay is well-suited for point-of-care, broad population testing, and applications in low-resource settings, for monitoring host humoral responses to vaccination or viral infection.
Read more
2020-12-07 (prnewswire.co.uk)
Broad Diagnostic Measures Remain Crucial as Vaccinations Near
/PRNewswire/ -- As of late last week, the U.S. has reported more than 14.3 million cases and over 278,400 deaths, according to Johns Hopkins University data....
Read more
2020-12-03 (prnewswire.co.uk)
Comprehensive Diagnostics Remains a Priority As More Surges are Expected
/PRNewswire/ -- When Pfizer and BioNTech SE announced earlier in November a request to the U.S. Food and Drug Administration (FDA) for Emergency Use...
Read more
2020-11-25 (prnewswire.co.uk)
Diagnostic Capabilities Remain of Utmost Importance as Cases Surge Worldwide
/PRNewswire/ -- As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, according to Johns Hopkins University data....
Read more
2020-11-24 (proactiveinvestors.co.uk)
Todos Medical installs automated lab equipment to boost coronavirus testing for Wisconsin client
The installation and scripting of new Tecan EVO200 and Tecan Fluent 780 systems, in combination with the use of Todos’ proprietary ANDis 350 automated...
Read more
2020-10-09 (proactiveinvestors.co.uk)
Todos Medical says it expects COVID-19 testing sales to drive business in the near term
Todos Medical CEO Gerald Commissiong believes the company has positioned itself as a ‘one stop shop’ for all things COVID testing related
Read more
2020-08-12 (marketscreener.com)
H1 2020: Strong demand for Tecan products to help in the global fight against the coronavirus pandemic | MarketScreener
Financial results for the first half of 2020 Surge in orders; order entry increased to CHF 374.0 million Increase of 24.3% in local currencies or 20.4% in Swiss francs Sales of... | August 12, 2020
Read more
2020-08-05 (marketscreener.com)
Tecan: Cooperation with Thermo Fisher in the area of Covid-19 test capacities | MarketScreener
The Tecan Group enters into a cooperation with Thermo Fisher Scientific. The aim is to significantly expand the testing capacities for Covid-19 worldwide, such as the Zurich... | 5 August 2020
Read more